Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck RotaTeq Observational Study For Intussusception Will Enroll 28,000

Executive Summary

A post-marketing observational study for Merck's RotaTeq will enroll 28,000 patients to track reports of intussusception and other potential adverse events, the company told FDA's Vaccines & Related Biological Products Advisory Committee at its Dec. 14 meeting

You may also be interested in...



GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support

With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan

GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support

With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan

Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads

Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq

Related Content

Topics

UsernamePublicRestriction

Register

PS046685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel